Topical GM-CSF hastens healing of leg ulcers in sickle cell disease

American Journal of Hematology

Volumn 76, Issue 2, 2004, Pages 192-

  Alikhan, Mir A ^a   Carter, Gary ^a   Mehta, Paulette ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA;

ADULT; BLOOD TRANSFUSION; CASE REPORT; CHRONIC DISEASE; CLINICAL FEATURE; COST OF ILLNESS; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; HEALTH CARE COST; HEMOGLOBIN SS DISEASE; HUMAN; LEG ULCER; LETTER; MALE; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SICKLE CELL CRISIS; SYMPTOM; WOUND HEALING;

ANEMIA, SICKLE CELL; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HUMANS; LEG ULCER; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 2542639444     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.20063     Document Type: Letter

References (5)

1. Platt OS, Brambilla DJ. Rosse WF, et al. Mortality in sickle cell disease. N Engl J Med 1996;330:1639-1644.
2. Pieters RC, Rojer RA. Saleh AW, Saleh AE, Dults AJ. Molgrastim to treat SS-sickle cell leg ulcers. Lancet 1995;345:528.
3. Groves RW, Schmidt-Lucke JA. Recombinant human GM-CSF in the treatment of poorly healing wounds. Adv Skin Wound Care 2000;13:107-112.
4. Chaine B, Neonato MG, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol 2001;137:467-470.
5. Cackovic M, Chung C, Bolton LL, Kerstein MD. Leg ulceration in the sickle cell patient. J Am Coll Surg 1998;187:307-309.